Want to see ABT full AI Analyst Report?
Revenue by Segment
Breaks down sales across Abbott’s main businesses—diagnostics, medical devices, nutrition, and established pharmaceuticals—showing which segments are driving revenue and margins. Helps investors see whether growth comes from higher-margin products (like diabetes device and diagnostic innovations) or volume businesses (nutrition/pharma), and where management is focused for future investment.
Medical Devices is the clear, durable growth engine and the main driver of margins, while Nutrition and Established Pharmaceuticals provide steady, defensive cash flow. Diagnostics has moved from pandemic peak into a lower base but the recent quarter’s pronounced uptick—consistent with management’s callout on cancer diagnostics and Exact Sciences contribution—could signal H2 acceleration; however, that recovery is tempered by weak rapid/molecular testing and China VBP headwinds. Watch sustainability of diagnostics momentum and timing of regulatory/reimbursement wins for material upside beyond devices.
ABT Revenue by Segment
| Date | Other | Diagnostics | Nutrition | Established Pharmaceuticals | Medical Devices |
|---|---|---|---|---|---|
| Sep 30, 2026 | $6.00M | $3.31B | $2.26B | $1.61B | $5.83B |
| Jun 30, 2026 | $5.00M | $3.09B | $2.14B | $1.50B | $5.85B |
| Mar 31, 2026 | $2.00M | $2.18B | $2.02B | $1.43B | $5.54B |
| Dec 31, 2025 | $5.00M | $2.46B | $1.94B | $1.38B | $5.67B |
| Sep 30, 2025 | $4.00M | $2.25B | $2.15B | $1.51B | $5.45B |
| Jun 30, 2025 | $5.00M | $2.17B | $2.21B | $1.38B | $5.37B |
| Mar 31, 2025 | $3.00M | $2.05B | $2.15B | $1.26B | $4.89B |
| Dec 31, 2024 | $5.00M | $2.52B | $2.13B | $1.27B | $5.05B |
| Sep 30, 2024 | $4.00M | $2.41B | $2.07B | $1.41B | $4.75B |
| Jun 30, 2024 | $4.00M | $2.19B | $2.15B | $1.29B | $4.73B |
| Mar 31, 2024 | $3.00M | $2.21B | $2.07B | $1.23B | $4.45B |
| Dec 31, 2023 | $4.00M | $2.53B | $2.04B | $1.22B | $4.44B |
| Sep 30, 2023 | $4.00M | $2.45B | $2.07B | $1.37B | $4.25B |
| Jun 30, 2023 | $3.00M | $2.32B | $2.08B | $1.29B | $4.29B |
| Mar 31, 2023 | $3.00M | $2.69B | $1.97B | $1.19B | $3.90B |
| Dec 31, 2022 | $3.00M | $3.31B | $1.82B | $1.22B | $3.75B |
| Sep 30, 2022 | $3.00M | $3.67B | $1.79B | $1.33B | $3.62B |
| Jun 30, 2022 | $2.00M | $4.32B | $1.95B | $1.22B | $3.76B |
| Mar 31, 2022 | $3.00M | $5.29B | $1.89B | $1.15B | $3.56B |
| Dec 31, 2021 | $3.00M | $4.47B | $2.04B | $1.20B | $3.75B |
| Sep 30, 2021 | $11.00M | $3.91B | $2.11B | $1.26B | $3.63B |
| Jun 30, 2021 | $22.00M | $3.25B | $2.11B | $1.18B | $3.67B |
| Mar 31, 2021 | $16.00M | $4.01B | $2.04B | $1.07B | $3.32B |
| Dec 31, 2020 | $16.00M | $4.34B | $1.94B | $1.15B | $3.26B |
| Sep 30, 2020 | $20.00M | $2.64B | $1.92B | $1.10B | $3.17B |
| Jun 30, 2020 | $15.00M | $1.99B | $1.88B | $1.01B | $2.42B |
| Mar 31, 2020 | $15.00M | $1.83B | $1.90B | $1.04B | $2.94B |
| Dec 31, 2019 | $10.00M | $2.06B | $1.87B | $1.17B | $3.20B |
| Sep 30, 2019 | $16.00M | $1.91B | $1.87B | $1.21B | $3.06B |
| Jun 30, 2019 | $16.00M | $1.91B | $1.88B | $1.11B | $3.08B |
| Mar 31, 2019 | $15.00M | $1.84B | $1.79B | $992.00M | $2.90B |